Area of research
Genetics · Hematology
Research interest
Research interests include Chronic Lymphocytic Leukemia Research, Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, and Lymphoma Diagnosis and Treatment.
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma
Genomics Define Malignant Transformation in Myeloma Precursor Conditions
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912
Non-CLL-type MBL and chip are associated precursor conditions: Insights from Mayo Clinic's MBL screening cohort
The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans
Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL)
CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myeloma
Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14)
ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma
Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
IKZF1/3 and CRL4<sup>CRBN</sup> E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma
Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial
High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
Targeted sequencing of relapsed/refractory myeloma patients identifies an enrichment of mutations in MAPK and Cereblon pathways
Targeted Sequencing of Relapsed/Refractory Myeloma Patients Identifies an Enrichment of Mutations in Cereblon and MAPK Pathways
RNAi screening of the kinome with cytarabine in leukemias
Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities